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Abstract: Renal carcinoma cells express Membrane Type 1-Matrix Metalloproteinase (MT1-MMP,
MMP-14) to degrade extracellular matrix components and a range of bioactive molecules to allow
metastasis and cell proliferation. The activity of MT1-MMP is modulated by the endogenous
inhibitors, Tissue Inhibitor of Metalloproteinases (TIMPs). In this study, we describe a novel
strategy that would enable a “designer” TIMP-1 tailored specifically for MT1-MMP inhibition
(V4A/P6V/T98L; Kiapp 1.66 nM) to be targeted to the plasma membrane for more effective MT1-MMP
inhibition. To achieve this, we fuse the designer TIMP-1 to the glycosyl-phosphatidyl inositol
(GPI) anchor of the prion protein to create a membrane-tethered, high-affinity TIMP variant named
“T1Pr αMT1” that is predominantly located on the cell surface and co-localised with MT1-MMP.
Confocal microscopy shows that T1Pr αMT1 is found throughout the cell surface in particular the
membrane ruffles where MT1-MMP is most abundant. Expression of T1Pr αMT1 brings about a
complete abrogation of the gelatinolytic activity of cellular MT1-MMP in HT1080 fibrosarcoma
cells whilst in renal carcinoma cells CaKi-1, the GPI-TIMP causes a disruption in MMP-mediated
proteolysis of ECM components such as fibronectin, collagen I and laminin that consequently triggers
a downstream senescence response. Moreover, the transduced cells also suffer from an impairment
in proliferation and survival in vitro as well as in NOD/SCID mouse xenograft. Taken together, our
findings demonstrate that the GPI anchor of prion could be exploited as a targeting device in TIMP
engineering for MT1-MMP inhibition with a potential in renal carcinoma therapy.
Keywords: MT1-MMP; TIMP; renal carcinoma; cancer therapy; prion; GPI anchor; protein engineering
1. Introduction
Membrane Type-1 Matrix Metalloproteinase (MT1-MMP, MMP-14) is a prominent member
of the zinc-dependent Matrix Metalloproteinase (MMP) family best known for its involvement in
the modulation of the extracellular environment and cellular processes such as cell invasion and
proliferation [1–3]. Among the large repertoire of extracellular matrix (ECM) and basement membrane
components cleaved by MT1-MMP are the adhesion molecules and fibrillar proteins fibronectin,
vitronectin, laminins, collagens I, II and III [4,5] as well as key signalling molecules implicated in
cancer dissemination such as CD44, syndecan-1, RANKL and MUC1 [6–9]. Like the other members
of the MMP family, MT1-MMP is a multi-domain proteinase consisting of a pro-domain, a catalytic
domain, a 4-bladed β-propeller-like hemopexin domain and a transmembrane domain followed by a
short cytoplasmic tail of only 20 amino acids [2]. Since its first appearance in the literature in the early
1990, MT1-MMP has been associated with cancer aggressiveness and its expression is widely accepted
as a good prognostic indicator of poor survival [8,10–13].
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The endogenous inhibitors of the MMPs, a group of structurally conserved proteins named
Tissue Inhibitor of Metalloproteinases (TIMP-1 to -4), are relatively small molecules varying between
21–26 kDa. TIMPs inhibit the MMPs by inserting their wedge-like N-terminal domains, an area
of the molecule termed “MMP-binding ridge,” into the catalytic clefts of the MMPs to form 1:1
tight-binding stoichiometric complexes that are essentially non-dissociable (examples include PDB
#4ILW, #3V96). Despite sharing a similar tertiary configuration, the TIMPs differ vastly in their MMP
selectivity. MT1-MMP, for instance, is sensitive to the inhibitory action of TIMP-2, -3 and -4 but
not TIMP-1; the same is true for MMP-19 [14–16]. In an effort to delineate the molecular basis of
TIMP-1’s selectivity, we have previously engineered a TIMP-1 variant named “T1MT1” that harbours a
triple mutation “V4A/P6V/T98L” at the MMP-binding ridge. With a Kiapp value of 1.66 nM against
MT1-MMP, the affinity of T1MT1 was practically indistinguishable from that of the TIMP-2 (Kiapp
1.30 nM), the natural inhibitor of MT1-MMP [14,17]. To further enhance the potency of T1MT1 against
MT1-MMP, we couple the TIMP to the glycosyl-phosphatidyl inositol (GPI) anchor of the prion
protein to create a membrane-tethered, high-affinity designer TIMP (named “T1Pr αMT1” hereafter)
that is primarily expressed on the cell surface and co-localised with cellular MT1-MMP. Here, we
show that not only could T1Pr αMT1 abolish the gelatin degrading ability of cellular MT1-MMP in
HT1080 fibrosarcoma cells, the TIMP was also capable of preventing renal carcinoma cell (CaKi-1)
tumorigenesis in in vitro and in vivo settings. Renal carcinoma is a highly metastatic and refractory
cancer type in which MT1-MMP is known to be overexpressed [12,18–20]. Our unique approach of
TIMP anchorage, we believe, may offer an opportunity for the development of novel therapeutics
aiming at renal carcinoma treatment.
2. Results
2.1. “T1Pr αMT1”: A Membrane-Tethered, High-Affinity Designer TIMP-1 Tailored Specifically for MT1-MMP
Inhibition
Listed in Figure 1A are the amino acid sequences of all the TIMP-1 constructs in this study.
Apart from the wild-type TIMP-1 (T1WT), we have created a GPI-anchored TIMP-1 (T1Pr) as well as a
GPI-anchored “designer” TIMP-1 named “T1Pr αMT1” tailored specifically for MT1-MMP inhibition.
With a Kiapp value just over 170 nM, T1WT is a known poor inhibitor of MT1-MMP. “T1Pr αMT1,”
by contrast, is a GPI-anchored “designer” TIMP-1 that carries a “V4A/P6V/T98L” triple mutation
tailored to fit the catalytic pockets of MT1-MMP [14,15]. As shown in the enclosed table, the affinity
of the TIMP for MT1-MMP (Kiapp 1.66 nM) is a vast improvement compared to that of the wild-type
TIMP-1. Affinity aside, another distinctive feature of T1Pr and T1Pr αMT1 noteworthy of interest is
their C-terminal sequences “QYERESQAYYQRGSSMVLFSSPPVILLISFLIFLIVG” that bear a sharp
resemblance to the signal peptide that encodes for human prion GPI anchor. Among the numerous
GPI signal sequences in the database, we intentionally chose the prion protein as a targeting device
due to the similarities in the way PrPSc (the scrapie form of prion) and MT1-MMP are localised at the
membrane ruffles [21]. By navigating to the vicinity of MT1-MMP, we hope to maximise the effect of
the TIMP at the site where its activity is most desired.
Enclosed in Figures 1B and A1 are reverse zymography gels illustrating the sequestration pattern
of the TIMPs following stable transduction in the renal carcinoma cells CaKi-1 (Figure 1B) and
fibrosarcoma cells HT1080 (Figure A2). While much of T1WT (ca. 26 kDa) was secreted to the
conditioned media, the GPI-anchored TIMP-1s T1Pr and T1Pr αMT1 were detected exclusively in the
membrane extracts (marked by asterisks *). There was no trace of the TIMPs in the conditioned media.
Subsequent immunostaining carried out under non-permeabilised conditions confirmed that T1Pr and
T1Pr αMT1 had indeed been immobilised on the cell surface as well as the cell edges where membrane
ruffling occurs (Figures 1C and A2; images captured with a fluorescent microscope).
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Figure 1. “T1Pr αMT1”: a GPI-anchored designer TIMP-1 tailored for MT1-MMP inhibition. (A) Top 
panel: Sequences of the wild type (T1WT) and designer TIMP-1s (T1Pr and T1Pr αMT1) tailored for MT1-
MMP inhibition. (1) T1WT: wild type TIMP-1 (2) T1Pr: GPI-anchored TIMP-1 (3) T1Pr αMT1: GPI-anchored 
“designer” TIMP-1 that carries a “V4A/P6V/T98L” triple mutation developed for MT1-MMP 
inhibition. Note that residues not native to TIMP-1 are boxed and highlighted in bold. Lower panel: 
inhibitory constant Kiapp of the designer TIMP-1 “T1Pr αMT1” against MT1-MMP. In contrast to T1WT 
which displayed a negligible affinity for MT1-MMP (Kiapp = 178 nM), the mutant T1Pr αMT1 was a superb 
inhibitor of the proteinase (Kiapp = 1.66 nM) [22]. (B) Sequestration of T1Pr and T1Pr αMT1 to the cell 
membrane of the renal carcinoma cells CaKi-1 as revealed by reverse zymography. While T1WT was 
secreted to the conditioned media, T1Pr and T1Pr αMT1 were sequestered exclusively to the cell 
membrane (GPI-anchored TIMPs highlighted by asterisks *). (C) Non-permeabilised immunostaining 
with a TIMP-1 antibody confirmed successful immobilisation of T1Pr and T1Pr αMT1 on CaKi-1 cell 
surface as visualised under a fluorescent microscope. The adjacent panels show the same cells stained 
with 4′,6-diamidino-2-phenylindole (DAPI). 
2.2. Localisation of T1Pr αMT1 on CaKi-1 Cell Surface and Membrane Ruffles 
To analyse the distribution pattern of the GPI-TIMPs in greater detail, we compiled a 3D figure 
of a CaKi-1 cell cluster transduced with T1Pr αMT1 using cross-sectional images from confocal 
microscopy. Contained in Figure 2A are two orthogonal views (Y vertical; X horizontal) illustrating 
T1Pr αMT1’s coverage of almost the entire cell surface (positions of the TIMP are indicated by arrow 
heads). Figure 2B, on the other hand, highlights how the designer TIMP was concentrated at the cell 
edges where membrane ruffles are the thickest. The results confirmed that T1Pr αMT1 had indeed been 
targeted to the cell surface as intended. 
Figure 1. “T1Pr αMT1”: a GPI-anchored designer TIMP-1 tailored for MT1-MMP inhibition. (A) Top
panel: Sequences of the wild type (T1WT) and designer TIMP-1s (T1Pr and T1Pr αMT1) tailored for
MT1-MMP inhibition. (1) T1WT: wild type TIMP-1 (2) T1Pr: GPI-anchored TIMP-1 (3) T1Pr αMT1:
GPI-anchored “designer” TIMP-1 that carries a “V4A/P6V/T98L” triple mutation developed for
MT1-MMP inhibition. Note that residues not native to TIMP-1 are boxed and highlighted in bold. Lower
panel: inhibitory constant Kiapp of the designer TIMP-1 “T1Pr αMT1” against MT1-MMP. In contrast to
T1WT which displayed a negligible affinity for MT1-MMP (Kiapp = 178 nM), the mutant T1Pr αMT1 was
a superb inhibitor of the proteinase (Kiapp = 1.66 nM) [22]. (B) Sequestration of T1Pr and T1Pr αMT1 to
the cell membrane of the renal carcinoma cells CaKi-1 as revealed by reverse zymography. While T1WT
was secreted to the conditioned media, T1Pr and T1Pr αMT1 were sequestered exclusively to the cell
membrane (GPI-anchored TIMPs highlighted by asterisks *). (C) Non-permeabilised immunostaining
with a TI P-1 antibody confir ed successful i obilisation of T1 r and T1 r MT1 on CaKi-1 cell
surface as visualised under a fluorescent microscope. The adjacent panels show the same cells stained
with 4′,6-diamidino-2-phenylindole (DAPI).
2.2. Localisation of T1Pr αMT1 on CaKi-1 Cell Surface and Membrane Ruffles
To analyse the distribution pattern of the PI-TI Ps in greater detail, we compiled a 3D figure of
a CaKi-1 cell cluster transduced with T1Pr αMT1 using cross-sectional images fro confocal microscopy.
Contained in Figure 2A are two orthogonal views (Y vertical; X horizontal) illustrating T1Pr αMT1’s
coverage of almost the entire cell surface (positions of the TIMP are indicated by arrow heads).
Figure 2B, on the other hand, highlights how the designer TIMP was concentrated at the cell edges
where membrane ruffles are the thickest. The results confirmed that T1Pr αMT1 had indeed been
targeted to the cell surface as intended.
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Figure 2. Cross-sectional views highlighting cellular localisation of T1Pr αMT1 in stably transduced 
CaKi-1 cells. CaKi-1 cells stably transduced with T1Pr αMT1 was immunostained with a TIMP-1 antibody 
under non-permeabilised conditions and visualised with an Airyscan confocal microscope. (A) 
Orthogonal views showing immobilisation of T1Pr αMT1 on the cell surface (indicated by arrowheads). 
(B) Concentration of T1Pr αMT1 at the cell edges as confirmed by 3D projection views of the membrane 
ruffles. 
2.3. Superb Co-Localisation of T1Pr αMT1 with Cellular MT1-MMP on the Cell Surface and Membrane Ruffles 
of CaKi-1 and HT1080 Cells 
Further immunostaining under non-permeabilising and permeabilising conditions showed that, 
not only could T1Pr αMT1 be detected in high abundance at the cell edges, it co-localised with MT1-
MMP throughout almost the entire cell perimeters (Figure 3A for CaKi-1; Figure A1 for HT1080). 
Besides co-localisation on the cell membranes, the TIMP also showed unmistakable signs of co-
localisation with MT1-MMP inside the cells. Figure 3B and Figure A2 are two collages of images that 
demonstrate the intracellular distribution patterns of T1Pr αMT1 under permeabilised staining 
conditions in the two cancer cell types. In comparison to T1Pr αMT1, T1Pr could also be detected in 
sections of the membrane ruffles although the overall intensity was much weaker presumably due to 
its lack of affinity for MT1-MMP. In addition to Figure 3A and B (and Figures A1, A2,), further 
evidence of T1Pr αMT1:MT1-MMP co-localisation is provided by the set of orthogonal images in Figure 
3C (and Figure A2) taken under non-permeabilised conditions that highlight the whereabouts of T1Pr 
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Figure 2. Cross-sectional views highlightin cellular loc lisation of T1Pr αMT1 in stably transduce
CaKi-1 cells. CaKi-1 cells stably transduced with MT1 was i munostained with a TIMP-1
antibody under non-permeabilised conditions and i l ith an Airyscan conf cal micros ope. (A)
Orthogonal views showing immobilisation of T1Pr αMT1 on the cell surface (indicated by arrowheads).
(B) Concentration of T1Pr αMT1 at ce l edges as confirmed by 3D projection views of the
membran ruffles.
2.3. Superb Co-Localisation of T1Pr αMT1 with Cellular MT1-MMP on the Cell Surface and Membrane Ruffles
of CaKi-1 and HT1080 Cells
Further immunostaining under non-permeabilising and permeabilising conditions showed
that, not only could T1Pr αMT1 be detected in high abundance at the cell edges, it co-localised
with MT1-MMP throughout almost the entire cell perimeters (Figure 3A for CaKi-1; Figure A1 for
HT1080). Besides co-localisation on the cell membranes, the TIMP also showed unmistakable signs
of co-localisation with MT1-MMP inside the cells. Figures 3B and A2 are two collages of images
that demonstrate the intracellular distribution patterns of T1Pr αMT1 under permeabilised staining
conditions in the two cancer cell types. In comparison to T1Pr αMT1, T1Pr could also be detected in
sections of the membrane ruffles although the overall intensity was much weaker presumably due
to its lack of affinity for MT1-MMP. In addition to Figure 3A,B (and Figures A1 and A2), further
evidence of T1Pr αMT1:MT1-MMP co-localisation is provided by the set of orthogonal images in
Figure 3C (and Figure A2) taken under non-permeabilised conditions that highlight the whereabouts
of T1Pr αMT1:MT1-MMP co-localisation at the membrane ruffles and cell surface.
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Figure 3. T1Pr αMT1:MT1-MMP co-localisation in stably transduced CaKi-1 cells. CaKi-1 cells stably 
transduced with the TIMPs were co-immunostained with antibodies against TIMP-1 and MT1-MMP 
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intense co-localisation of T1Pr αMT1 with MT1-MMP at the perinuclear regions as well as membrane 
ruffles. (C) Intense T1Pr αMT1:MT1-MMP co-localisation at the cell ruffles as highlighted by non-
orthogonal (left) and orthogonal (right) views of the same CaKi-1 cell. Arrowheads A, B, C and D in 
the panels denote the same cell sites as viewed from a non-orthogonal (left) and orthogonal (right) 
perspectives. 
2.4. T1Pr αMT1 Abolishes MT1-MMP-Mediated Gelatinolytic capability of HT1080 in Cell-Based Setting 
To assess the inhibitory potency of T1Pr αMT1 against native MT1-MMP in a cell-based 
environment, we also transduced the TIMPs into the metastatic fibrosarcoma cells HT1080 which 
have been previously shown to exhibit a strong gelatin-degrading proficiency on immobilised 
fluorescent gelatin [22]. Though not an exclusive assay for MT1-MMP, the experiment should provide 
us with a clue as to the potency of the TIMPs against the protease under cellular setting. Figure 4A is 
a collection of images that succinctly summarise the relative potency of the various TIMPs against 
cellular MT1-MMP. In contrast to the large and occasionally smudgy splotches detected in the empty 
vector, T1WT and T1Pr chambers, there was almost no sign of gelatin degradation in the slide in which 
T1Pr αMT1-transductants occupied. 
Figure . r MT1:MT1- MP co-localisation in stably transduced CaKi-1 cells. CaKi-1 ce ls stably
transduced ith the TI Ps ere co-i unostained ith antibodies against TI P-1 and T1- P
under non-per e ili i ili i i i . il i l Pr:MT1- P was
eak and limited to the cell edges, T1Pr αMT1 c l-localised with MT1-MMP intensely throughout
the ntire cell surface and much of the membrane ruffles. (B) Permeabilised immunostaining
showing intense co-localisation of T1Pr αMT1 with MT1-MMP at the perinuclear regions as well as
membrane ruffles. (C) Intense 1Pr αMT1:MT1-MMP co-localisation at the cell ruffles as highlighted
by non-orthogonal (left) and orthogonal (right) views of the same CaKi-1 cell. Arrowheads A, B, C
and D in the panels denote the same cell sites as viewed from a non-orthogonal (left) and orthogonal
(right) perspectives.
2.4. T1Pr αMT1 Abolishes MT1-MMP-Mediated Gelatinolytic Capability of HT1080 in Cell-Based Setting
To assess the inhibitory potency of T1Pr αMT1 against native MT1-MMP in a cell-based
environment, we also transduced the TIMPs into the metastatic fibrosarcoma cells HT1080 which have
been previously shown to exhibit a strong gelatin-degrading proficiency on immobilised fluorescent
gelatin [22]. Though not an exclusive assay for MT1-MMP, the experiment should provide us with
a clue as to the potency of the TIMPs against the protease under cellular setting. Figure 4A is a
collection of images that succinctly summarise the relative potency of the various TIMPs against
cellular MT1-MMP. In contrast to the large and occasionally smudgy splotches detected in the empty
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vector, T1WT and T1Pr chambers, there was almost no sign of gelatin degradation in the slide in which
T1Pr αMT1-transductants occupied.
Further immunostaining and zymography analysis carried out on the cell lysates and conditioned
media of stably transduced HT1080 and CaKi-1 cells indicated no change in MT1-MMP expression as
well as pro-MMP-2 processing patterns as a result of the TIMPs’ expression (Figure 4B,C).
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2.5. T1Pr αMT1 Expression Triggers Cellular Senescence in CaKi-1 Cells
A distinctive feature of T1Pr αMT1-transduced CaKi-1 cells we noticed during the course of this
study was their excessively slow proliferation rate in 2D culture conditions. Indeed, the typical
proliferation rate of T1Pr αMT1-transductants was no higher than 26% of that of the empty vector
and T1WT controls (Figure 5A). Apart from a sluggish growth rate, the cells also appeared unusually
stretched without a defined shape or boundary (Figure 5B; enlarged images in insets). Suspected to
be signs of cellular senescence, we thus examined the level of senescence-associated β-galactosidase
(SA-β-Gal) activity of the transductants using X-gal as a substrate [23]. Figure 5C shows that, whilst
only a small proportion (2–4%) of the empty vector-, T1WT- and T1Pr-transduced cells developed blue
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colour upon incubation with X-gal, intense staining were detected in T1Pr αMT1-transductants. With
an average percentage of blue cells approaching 50%, the incidence of senescing cells in T1Pr αMT1
population was far higher than those of the other TIMP transductants (* p < 0.01).
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developed into colonies of irregular size in excess of 100 μm within 25 days of seeding. While the 
impact of T1WT was minimal, T1Pr appeared to exhibit an inhibitory effect though not by a large 
margin. T1Pr αMT1, in contrast, demonstrated an impressive anti-tumorigenesis efficacy as there were 
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Figure 5. T1Pr αMT1 triggers cellular senescence in CaKi-1 cells as well as inhibits CaKi-1 proliferation
in Matrigel suspension. (A) T1Pr αMT1-transduced CaKi-1 cells proliferated at a substantially slower
rate than its T1WT and T1Pr counterparts under 2D culture conditions (* p < 0.05 vs. T1Pr). (B) In
contrast to the typical phenotypic appearance of epithelial cells, T1Pr αMT1-transduced CaKi-1 cells
appeared unusually large and “stretched” with no defined shape or boundary. Insets: close-up images
highlighting the morphological difference between the empty vector- and T1Pr αMT1-transductants.
(C) T1Pr αMT1 triggered an upsurge of SA-β-gal activity as demonstrated by X-gal staining (* p < 0.01
vs. other TIMPs). (D) While many of the empty vector-, T1WT- and T1Pr-transduced CaKi-1 cells
developed into colonies > 100 µm within 25 days of incubation in Matrigel, T1Pr αMT1-transductants
proliferated at a substantially slower rate (* p < 0.01 vs its runner up T1Pr). Results in the bar chart
represent the average of three technical repeats ± S.E.M.
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The effects of T1Pr αMT1 on cell proliferation is even more pronounced in the confine of Matrigel
suspension. As shown in Figure 5D, without interference from the TIMPs, control CaKi-1 cells rapidly
developed into colonies of irregular size in excess of 100 µm within 25 days of seeding. While the
impact of T1WT was minimal, T1Pr appeared to exhibit an inhibitory effect though not by a large
margin. T1Pr αMT1, in contrast, demonstrated an impressive anti-tumorigenesis efficacy as there were
far fewer colonies that reached 100 µm by the end of the incubation period (*p < 0.01 vs. T1Pr).
2.6. T1Pr αMT1 Expression Causes Accumulation of Fibronectin, Collagen I and Laminin at the Pericellular
Matrices
Given the pivotal role MT1-MMP plays in ECM turnover and modulation, we were keen to find
out if the uncharacteristic cell behaviours observed in Figure 5 were the outcomes of an altered cellular
microenvironment. To this end, we stained the cells with a range of ECM antibodies and the results
are summarised in Figure 6. In total contrast to the near-barren scenes observed in the empty vector-,
T1WT- and T1Pr-transductants, there was a large amount of the macromolecules fibronectin, collagen I
and laminin in the slides on which T1Pr αMT1-transductants were cultured. Another observation of
interest in the figure is the rather dense and disorderly extracellular fibronectin/collagen I bundles
that did not appear to follow an organised or recognisable pattern.
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Immunostaini g showing accumulatio of (A) Fibro ectin (B) Collagen I a d (C) laminin in
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2.7. T1Pr αMT1 Inhibits CaKi-1 Growth in NOD/SCID Xenograft
Under in vivo conditions, the anti-proliferative effect of T1Pr αMT1 was equally, if not more
impressive. Figure 7A is a summary of our findings on day-57 when the study reached a humane
endpoint (n = 8). Without the suppressive effect of T1Pr αMT1, CaKi-1 tumours rapidly emerged in every
control NOD/SCID mouse within 10 days of inoculation. Uninterrupted tumour growth was recorded
in all the control mice from day-10 to -57 when the average tumour volume reached a very substantial
3,810 mm3. In contrast, T1Pr αMT1 tumours only started to appear after 20 days of inoculation. By
the time the experiment was concluded on day-57, the average tumour volume for T1Pr αMT1 was no
higher than 750 mm3, a fraction (20%) of that of the control group.
The individual masses for all the tumours following post-mortem surgery are shown in the
scattered chart in Figure 7B. While the control tumours were all ranged within 1298–3005 mg (average
= 2256 mg), the average mass for T1Pr αMT1 tumours was only 491 mg, a mere 22% of that of the control
group (* p < 0.01).Molecules 2019, 24, x FOR PEER REVIEW 10 of 16 
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3. Discussion
The findings in this study are significant for two reasons. First and foremost, our results have
proven for the first time that the prion molecule, notwithstanding its infamy as an infectious agent,
can be exploited as a targeting device in TIMP engineering. Collective evidence from microscopy,
biochemical and cell-based assays, as we have shown here, are all unequivocally supportive of the
use of the prion GPI as a means of targeting TIMP-1 to cellular MT1-MMP. The second significance
of our findings lies in the demonstration of the anti-tumorigenesis efficacy of T1Pr αMT1 in the renal
carcinoma cells CaKi-1. Renal carcinoma is a highly invasive and refractory cancer type for which there
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is no effective conventional therapy [18]. The invasive potential of the cancer, as shown by Petrella and
co-workers, is linked to MT1-MMP not only through its function as a major matrix-degrading enzyme
but also the mediating role it plays in the cleavage of adhesion molecules and other MMPs [12,20]. As
such, there have long been calls for MT1-MMP to be listed as a prime target for therapeutic intervention
in various types of invasive cancers including renal carcinoma [4,5,12].
Based on the data obtained, we can construct a rather straightforward rationale to explain the
effectiveness of T1Pr αMT1 as seen in the animal study. As evident from the microscopy images in
Figure 2, T1Pr αMT1 is expressed and segregated primarily at the membrane ruffles where MT1-MMP
is mostly found. Given the TIMP’s in-built affinity for MT1-MMP (Kiapp 1.66 nM; Figure 1),
the inhibitor:enzyme interaction that ensues would inevitably lead to a downregulation in the
proteolytic functions of MT1-MMP—a fact clearly reflected by the outcomes of the gelatinolytic
assay in Figure 4. Inactivation of MT1-MMP, in turn, causes a disruption in ECM turnover as
exemplified by evidence of fibronectin/collagen I/laminin accumulation in Figure 6. Maintenance of
normal mechanical properties of the ECM is fundamental to cellular and tissue health (reviewed by
Humphrey et al. [24]). A dramatic alteration in ECM homeostasis, as in the case of T1Pr αMT1, would
likely bring about a disruption in normal “mechano-transduction” signalling between the nucleus and
extracellular compartments. A direct consequence of a mechano-transduction failure, as reviewed
by Humphrey et al., is a senescence response characterised by cell hypertrophy, a slowdown in
proliferation and an upsurge in SA-β-gal activity as demonstrated in Figure 5 [24]. As a consequence
of the T1Pr αMT1-transductants’ inability to modulate the extracellular microenvironment in order to
undergo cytoskeletal reorganisation required for proliferation, the T1Pr αMT1 inoculums thus failed to
adapt and prosper in the newly introduced in vivo environment [25].
4. Materials and Methods
4.1. Materials
All the reagents used in this study were supplied by ThermoScientific USA (Waltham, MA,
USA) unless otherwise stated. Antibodies against TIMP-1 (Abcam: Ab1827) (Cambridge, MA, USA),
MT1-MMP (Abcam: Ab38970), fibronectin (R&D Systems: MAB 19181) (Minneapolis, MN, USA),
collagen I (Abcam: Ab34710) and laminin (Abcam: Ab11575) were purchased either from R&D Systems
or Abcam, USA. Senescence detection kit and Matrigel® were products from Biovision (San Francisco,
CA, USA) and BD Biosciences (San Jose, CA, USA). HT1080 and CaKi-1 cell lines were acquired from
the Shanghai Cell Repository, Chinese Academy of Science (Shanghai, China).
4.2. Cloning, Lentiviral Transduction, Reverse Zymography and Immunofluorescence Microscopy
The procedure for the creation of the soluble domain of T1Pr αMT1 by site-directed mutagenesis
has been described in our previous paper [14]. The C-terminal prion tag was added by
overlapping polymerase chain reaction (PCR) with three reverse primers bearing the following
sequences (5′-GGCCTGAGATTCCCTCTCGTACTGGGCTATCTGGGACCGCAGGGACTG-3;
5′-CACAGGTGGGGAGGAGAAGAGGACCATGCTCGATCCTCTCTGGTAATAGGCCTGAGATTC
CCTCTCGTACTG-3′ and 5′-TAAACGGGCCCTCATCCCACTATTAGGAAGATGAGGAAAGA
GATCAGGAGGATCACAGGTGGGAGGAGAAGAGGAC-3′) with Pwo DNA polymerase. The PCR
amplicon was digested with EcoR I and Apa I restriction enzymes before being subcloned into a
pLVX-puro vector (Takara) for lentiviral packaging. All the clones generated in this study had been
sequenced in both strands to confirm that no unwanted mutation had been introduced into the cDNAs
during the PCR and cloning processes. The procedures for TIMP lentiviral transduction and reverse
zymography were essentially identical to the ones elaborated previously [22]. For immunofluorescence,
cells seeded in Nunc® Lab-Tek II Chamber Slides® were fixed in 4% paraformaldehyde prior to
blocking with 5% bovine serum albumin in phosphate buffer saline (PBS). Following overnight
incubation in primary antibodies at 4 ◦C, the cells were rinsed with PBS before further incubation
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in Alexa Fluor® 488 (or 555)-conjugated anti-mouse and/or anti-rabbit secondary antibodies. Cell
visualisation was performed with a Zeiss LSM880 Airyscan® confocal microscope usually under 20×
or 40×magnification.
4.3. Gelatin Degradation Assay
HT1080 cells transduced with the TIMPs (approximately 1000 cells) were seeded overnight in
Nunc® Lab-Tek II Chamber Slides® pre-coated with 0.5 mg/mL porcine Oregon Green® 488-conjugated
fluorescent gelatin. Following fixation in paraformaldehyde, the slides were probed with an
anti-MT1-MMP antibody before visualisation with a Nikon Eclipse Ni fluorescent microscope for
degraded gelatin patches.
4.4. Cellular Senescence Assay with X-Gal
Caki-1 cells stably transduced with the TIMPs were cultured in a 12-well plate for at least 10 days
before staining with X-gal as per manufacturer’s instructions. Following brief washing with PBS, the
cells were examined under a Nikon Eclipse Ti inverted microscope for signs of blue precipitates.
4.5. Renal Carcinoma Clonogenic Development in Matrigel
Clonogenic assay in Matrigel was carried out essentially as described [26]. The number of colonies
> 100 µm after 25 days of incubation were counted and averaged for analysis. To ensure reliability, the
assay had been performed in duplicate for at least three times.
4.6. Tumour Development Study in Non-Obese Diabetic/Severe Combined Immuno-Deficient (NOD/SCID)
Model
All the experiments involving the use of animals were performed at GenePharma Co. Ltd. (animal
licence registration number SYXK (Su) 2014-0054), Singapore Industrial Park, Biobay, Suzhou in strict
accordance to the regulations outlined in the National Guidance for Animal Care, China. For growth
evaluation, 4 × 106 cells in 30% Matrigel/DMEM suspension were inoculated subcutaneously to the
left or right flanks of 6-week old male NOD/SCID mice (n = 8 per group) to allow tumour development
for 57 days. To calculate the tumour volume, the following formula was employed: Volume = Length ×
(Width)2 × pi/6 where the width is defined as the smaller of the two perpendicular diameters. To ensure
reproducibility, the experiment had been independently performed twice. This study does not require
the use of human participants, data or tissues.
4.7. Statistical Analysis
Statistical analysis was carried out using the online calculator in the www.socscistatistics.com website.
Statistical significance was determined by Student’s t-test usually under a two-tailed hypothesis.
5. Conclusions
In conclusion, we have shown that the GPI anchor of the prion molecule could be exploited
as a molecular device for TIMP targeting. T1Pr αMT1, the GPI-anchored designer TIMP-1 created in
this study, is a potent MT1-MMP inhibitor with the potential of being further developed into an
experimental therapeutic for renal carcinoma treatment. We are currently testing the efficacy of the
TIMP against a range of cancers using approaches including purified proteins as well as adenoviral
delivery system. The results will be made public upon complete satisfaction of all the patenting criteria.
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Figure A1. Immobilisation of T1Pr and T1Pr αMT1 on the membrane of fibrosarcoma cells HT1080. (A) 
Sequestration of T1Pr and T1Pr αMT1 to the membrane of HT1080 cells as shown by reverse zymography. 
(B) Non-permeabilised immunostaining with a TIMP-1 antibody confirmed immobilisation of T1Pr 
and T1Pr αMT1 on HT1080 cell surface. The adjacent panels show the same cells stained with DAPI. 
Figure A1. I ilisati of T1Pr and T1PrαMT1 on the membrane of fibrosarcoma cells
HT1080. (A) Sequestration of T1Pr and T1Pr αMT1 to the membrane of HT1080 cells as shown by
reverse zymography. (B) Non-permeabilised immunostaining with a TIMP-1 antibody confirmed
immobilisation of T1Pr and T1Pr αMT1 on HT1080 cell surface. The adjacent panels show the same cells
stained with DAPI.
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Figure A2. Co-localisation of T1Pr αMT1 with MT1-MMP in stably transduced HT1080 cells. Stably 
transduced HT1080 cells were co-immunostained with antibodies against TIMP-1 and MT1-MMP 
under non-permeabilising and permeabilising conditions. (A) Superb co-localisation of T1Pr αMT1 with 
MT1-MMP throughout the entire cell surface and membrane ruffles. (B) Permeabilised 
immunostaining showing intense T1Pr αMT1:MT1-MMP co-localisation at the membrane ruffles. (C) 
Orthogonal views highlighting co-localisation of T1Pr αMT1 with MT1-MMP on the cell surface and 
membrane ruffles (T1Pr αMT1:MT1-MMP co-localisation indicated by arrow heads). 
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